drugset / Trial / NCT04943289

Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis

NCT04943289 ↗

Phase 1 Completed 20 enrolled Joanne Kurtzberg, MD
NaSingle-groupOpen-labelTreatment

Summary

This study is a prospective Phase 1a open-label single- center trial. It will assess the safety of intrathecal administration of DUOC-01 cells to adults with Primary Progressive Multiple Sclerosis (PPMS). DUOC-01 is a population of cells expanded from donated human umbilical cord blood cells and is intended for treatment of neurodegenerative and demyelinating diseases. There will be approximately 20 participants enrolled. Exploratory objectives include changes in MS assessment scores, changes in brain MRI findings, and changes in blood biomarkers.

Timeline

Start
2021-01-24
Primary completion
2025-09-30
Completion
2025-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject DUOC-01 Cell therapy 1e+07 cells Intrathecal
Subject DUOC-01 Cell therapy 2.5e+07 cells Intrathecal
Subject DUOC-01 Cell therapy 5e+07 cells Intrathecal